Cowen & Co. Initiates Coverage of Bruker with Outperform Rating | GenomeWeb

NEW YORK (GenomeWeb News) – Cowen & Co. today started covering Bruker, giving it an Outperform rating and a $21 price target.

In a research report, analyst Doug Schenkel said that while Bruker has challenges ahead and near-term catalysts for its shares are not obvious, "we are enthused about the long-term potential and associated unlocking of significant value; we view the risk/reward as very compelling for investors with an 18-24 month investment horizon."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.